Tuberculosis and Respiratory Diseases10.4046/trd.2018.0004201982162Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung AdenocarcinomaSeo Yun Kim, Jae Kyung Myung, Hye-Ryoun Kim, Im Il Na, Jae Soo Koh, Hee Jong Baek, Cheol Hyeon Kim,,
OncoTargets and Therapy10.2147/ott.s957852016355Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutationsYan Li, Ruiguang Zhang, Xiu Nie, Xiaorong Dong, Gang Wu
Lung Cancer10.1016/j.lungcan.2015.06.0082015893337-342Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patientsLing Shan, Ziping Wang, Lei Guo, Hongyan Sun, Tian Qiu, Yun Ling, Wenbin Li, Lin Li, Xiuyun Liu, Bo Zheng, Ning Lu, Jianming Ying,
OncoTargets and Therapy10.2147/ott.s2795402021Volume 1313425-13435The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI TherapyWen-Chien Cheng, Te-Chun Hsia, Chih-Yen Tu, Hung-Jen Chen,
Lung Cancer10.1016/j.lungcan.2013.07.0182013821177-178NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKIFrancesco Facchinetti, Marcello Tiseo, Letizia Gnetti, Enrico Maria Silini, Andrea Ardizzoni,
Lung Cancer: Targets and Therapy10.2147/lctt.s1243012017Volume 821-30Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective studySeigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta,
Annals of Oncology10.1093/annonc/mdx671.017201728x130Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patientsW. Zhuang, C. Xu, W. Wang, Z. Song, Y. Zhu, R. Chen, Y. Guan, X. Yi, M. Fang, G. Chen, T. Lv, Y. Song,,
Journal of Experimental & Clinical Cancer Research10.1186/1756-9966-31-652012311Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFRFen Wang, , Shuhang Wang, Zhijie Wang, Jianchun Duan, Tongtong An, Jun Zhao, Hua Bai, Jie Wang,,
10.21203/ EGFR-TKI Therapy for EGFR-Mutant NSCLC in Traditionally Unresectable PatientsKe-Cheng Chen, Shuenn-Wen Kuo, Chen-Hao Hsiao, Jing-Shing Chen,
OncoTargets and Therapy10.2147/ott.s1266132017Volume 10447-452Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinomaShen-Cun Fang, Hai-Tao Zhang, Ying-Ming Zhang, Wei-Ping Xie,